A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease.

Girish N Nadkarni^1,2, Dipti Takale³, Bruce Neal⁴, Kenneth W Mahaffey⁵, Yshai Yavin⁶, Michael K Hansen⁶, Fergus Fleming⁷, Hiddo J L Heerspink⁸, Steven G Coca²

¹Division of Data-Driven and Digital Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.

²The Barbara T. Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York.

³Persistent Systems, Pune, India.

⁴The George Institute for Global Health, UNSW Sydney, Sydney, Australia.

⁵Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California.

⁶Janssen Research and Development, LLC, Spring House, Pennsylvania.

⁷Renalytix, New York, New York.

⁸Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.

PubMed PMC DOI PDF

Abstract

KidneyIntelX, a bioprognostic test for assessing risk of CKD progression, risk stratified individuals for kidney, heart failure, and death outcomes in the Canagliflozin Cardiovascular Assessment Study.Individuals scored as high risk seemed to derive more of benefit from treatment with canagliflozin versus placebo.These findings may serve to increase adoption of underutilized therapies for cardiore…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.